Anjali Vaidya, MD, is the director of the Advanced Pulmonary Hypertension, Right Heart Failure & CTEPH Program and the Pulmonary Hypertension Fellowship at Temple University Hospital and a professor of medicine at Temple University

The Mechanics Behind PAH Diagnosis and Management, With Anjali Vaidya, MD

In 2022, the European Society of Cardiology (ESC) released a set of comprehensive clinical guidelines for the detection and management of 

, emphasizing the importance of a multidisciplinary approach.

American College of Cardiology (ACC) Scientific Sessions 2026

 in New Orleans, Louisiana, Anjali Vaidya, MD, assistant dean at the Lewis Katz School of Medicine and director of advanced pulmonary hypertension, right heart failure, and the CETPH Program at Temple Health, spoke on the implementation of these guidelines. The editorial team at 

 met with Vaidya at the conference to learn more.

“The guidelines have evolved a lot over the years, which has been a wonderful thing to see,” Vaidya told 

. “But the inclusion of imaging modalities, and particularly electrocardiography, has really expanded in those guidelines. More and more advancement is being made, and more parameters are being included – I think we’ll continue to see that grow even further with the next iteration of guidelines.”

The ESC guidelines focus heavily on reanalyzing the hemodynamic definition of PAH. The authors officially updated the condition’s classification, repositioning vasoreactive patients with idiopathic PAH and developing a new algorithm for earlier detection of PAH in the community. The document also posits new, expedited screening and referral strategies.

Vaidya notes, however, that the most impactful aspect of the current guidelines is the emphasis on imaging in patients with PAH. Echocardiographic and cardiac magnetic resonance imaging (cMRI) parameters are proposed within the document, aiming to help clinicians monitor right ventricle function during the disease’s progression.

“The highest yield of imaging modality for pulmonary hypertension diagnosis is going to be echocardiography, or ultrasound of the heart, from an imaging perspective,” Vaidya said. “This is embedded in all of the pulmonary hypertension guidelines for diagnosis, and there are a lot of different parameters that can be interpreted to give us clues into the diagnosis of pulmonary hypertension.”

Vaidya also provides advice for clinicians entering the sphere of PAH management. She guides newcomers to make themselves familiar with the actual data of their patients rather than allowing technology to manage the numbers. Vaidya emphasizes the importance of being able to interpret data oneself to avoid mechanical errors or complications and to become more familiar with the condition and its effects.

“The most important thing is to practice and become comfortable with looking at the imaging directly rather than relying on reports,” Vaidya said. “There’s so much information available when you look at the pictures of cardiovascular structures, whether that’s on chest X-ray or CT scan or echocardiography, that is sometimes nuanced and subtle, so the biggest first step is to take a dive into it and open those images directly to become more and more comfortable with interpreting and not missing clues.”

Editors’ Note: Vaidya reports disclosures with Bayer, Janssen, Merck, and United Therapeutics.

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618-3731. 

Videos

Vaidya discusses the 2022 pulmonary arterial hypertension guidelines and how they can be made more accessible for clinicians just entering the field.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Strategic Alliance Partnership

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The first quarter of 2026 marked a pivotal period in nephrology, with major regulatory decisions, guideline updates, and late-phase clinical trial readouts reshaping the treatment landscape for chronic kidney disease (CKD) and glomerular disorders. The US Food and Drug Administration advanced multiple high-impact therapies across focal segmental glomerulosclerosis (FSGS), IgA nephropathy (IgAN), and dialysis-related complications, including priority review for atacicept and continued evaluation of sparsentan and oxylanthanum carbonate. At the same time, the Kidney Disease: Improving Global Outcomes released its 2026 Clinical Practice Guideline for anemia in CKD, introducing updated recommendations on iron therapy, erythropoiesis-stimulating agents, and transfusion strategies, with an increased emphasis on individualized, symptom-driven care.

Parallel to these regulatory and guideline shifts, phase 2 and 3 trial data underscored continued momentum in precision nephrology and immunologic targeting. Studies such as TACITO, MAJESTY, and RAINIER highlighted emerging therapies ranging from microbiome-modulating strategies in kidney cancer to B-cell–targeted approaches and novel immunotherapies for proteinuric kidney diseases. Together, these developments reflect a rapidly evolving nephrology pipeline, with growing therapeutic diversity and a stronger focus on disease modification.

Beyond clinical and regulatory advances, thought leadership in the field continued to expand the conversation around kidney disease. Coverage this quarter explored the intersection of social determinants and CKD outcomes, as well as the accelerating pace of discovery in glomerular disease, reinforcing a broader shift toward holistic, patient-centered, and biologically driven care in nephrology.

Catch up on any of the FDA news, trial updates, and featured content you missed in Q1 2026.

FDA Extends Sparsentan (Filspari) sNDA Review for Focal Segmental Glomerulosclerosis

On January 13, 2026, the FDA announced its extended review of the supplemental New Drug Application (sNDA) for sparsentan (Filspari) to treat focal segmental glomerulosclerosis (FSGS). After the drug received a Major Amendment, the FDA moved the new PDUFA target action date to April 13, 2026

FDA Grants Priority Review Of Biologics License Application For Atacicept In IgA Nephropathy

for adults with IgAN received priority review of its Biologics License Application, supported by interim data analysis from ORIGIN 3, which met its primary endpoint of proteinuria reduction at week 36, with a 46% reduction compared to baseline, and a 42% reduction compared to placebo (

FDA Accepts Oxylanthanum Carbonate NDA Resubmission for Hyperphosphatemia in CKD, Dialysis

The FDA accepted Unicycive Therapeutics’ NDA for oxylanthanum carbonate (OLC) for the treatment of hyperphosphatemia in patients with CKD on dialysis on January 29, 2026. The Agency has deemed the OLC resubmission to be a Class II complete response, which has a 6-month review period from the date of resubmission. The PDUFA target action date is June 29, 2026.

KDIGO Releases New Guideline for Anemia in Chronic Kidney Disease

On January 5, 2026, KDIGO Anemia Work Group released the 2026 Clinical Practice Guideline for the Management of 

 in CKD. Broken down into 4 main chapters, the first addresses the diagnosis and evaluation of anemia and iron deficiency in patients with CKD, including prevalence, pathophysiology, and clinical outcomes. The second focuses on iron therapy for anemia in CKD and prioritizes intravenous iron over oral formulations. The third chapter covers the use of erythropoiesis-stimulating agents and HIF-PHIs to raise hemoglobin, emphasizing shared decision-making and evaluation of alternative causes before treatment initiation. Lastly, the fourth outlines appropriate use of RBC transfusions, highlighting potential risks and recommending symptom-based assessment rather than hemoglobin thresholds alone.

TACITO: Fecal Microbiota Transplantation Improves Immunotherapy Response in Advanced Kidney Cancer

New evidence from the ​​phase 2a TACITO trial suggests FMT improves the effectiveness of immunotherapy in patients with advanced mRCC receiving pembrolizumab and axitinib, based on a hypothesis that transplanting favorable gut microbiome could enhance a patient’s response to immunotherapy.

MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous Nephropathy

MAJESTY, the first global phase 3 study in primary membranous nephropathy (PMN), met its primary endpoint of complete remission at 2 years with obinutuzumab (Gazyva).

Genentech announced the positive 2-year phase 3 results of obinutuzumab compared to tacrolimus on February 16, 2026, with the potential for the therapeutic to become the first approved treatment for PMN.

RAINIER: Povetacicept Reduces Proteinuria By 52.0%

Povetacicept met its primary and secondary endpoints in RAINIER, an ongoing phase 3 trial evaluating adults with IgA nephropathy (IgAN), according to a 36-week interim analysis. Vertex Pharmaceuticals announced positive results where povetacicept showed a 52.0% reduction in urine protein to creatinine ratio (UPCR) compared to baseline, with a statistically significant and clinically meaningful 49.8% UPCR reduction compared to placebo (

Crisis Point: The Cause and Calamity, Neighborhood Disadvantage and Kidney Disease

Clinicians often thought of healthcare as having a problem and a solution, but this Crisis Point examined what was going on underneath the surface. With the rising threat of chronic kidney disease, more was at stake than the values measurable in a lab, this piece focused on the detrimental problem of neighborhood disadvantage as both the cause and the calamity of kidney disease.

ISGD and the Fastest 5 Years in Glomerular Disease

For experts from ISGD, the last 5 years were the fastest and most dynamic period in glomerular disease. In this special report, Barbara Gillespie, MD, an adult nephrologist at the University of North Carolina and Chief Medical and Strategy Officer at ISGD, and Toby Huber, MD, head of Internal Medicine at Hamburg-Eppendorf in Germany and founding president of ISGD, broke down the scientific advances and how they revolutionized biological understanding of glomerular diseases.

Articles

Q1 2026 delivered significant inflection points in nephrology across FSGS, IgA nephropathy, anemia of CKD, and dialysis-related mineral metabolism. Regulatory momentum included an extended FDA review timeline for sparsentan in FSGS, priority review for atacicept in IgAN, and a new PDUFA clock for oxylanthanum carbonate in dialysis hyperphosphatemia. KDIGO’s 2026 anemia guideline update sharpened recommendations around IV iron preference, judicious ESA/HIF-PHI use with shared decision-making, and symptom-based transfusion strategies. Late-phase readouts advanced immunologic and precision approaches, alongside increased attention to social determinants shaping CKD outcomes.

Catch up on nephrology headlines you missed from Q1 2026.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

FDA News

Q1 2026 Recap: Nephrology News and Updates

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Endocrinology is off to a stellar start in 2026, with a first quarter packed full of major FDA approvals and trial results. Orforglipron, now approved for 

, demonstrated some of its best trial performance in February, while the investigational triple agonist retatrutide demonstrated solid safety data in the same disease. Meanwhile, the 

 fired off a volley of approvals, covering the first once-weekly basal insulin for T2D, inhaled insulin powder for 

, and setmelanotide for the rare and previously poorly-managed acquired hypothalamic 

With so much practice-changing news arriving over the last 3 months, 

 has collected 9 of the most impactful headlines from this first quarter. Catch up on any big news you may have missed below:


FDA Approves Insulin Icodec (Awiqli) as First Once-Weekly Basal Insulin for Type 2 Diabetes


On March 26, 2026, the FDA approved insulin icodec-abae as the first and only once-weekly basal insulin for the improvement of glycemic control as an adjunct to diet and exercise in patients with T2D. Under the brand name Awiqli, this is the first new class of basal insulin to reach US patients in over 2 decades. The approval was based on the ONWARDS clinical program, including 4 clinical trials evaluating insulin icodec against standard once-daily basal insulins.


FDA Approves Setmelanotide (Imcivree) for Acquired Hypothalamic Obesity


On March 19, 2026, the FDA announced its approval of an expanded indication for setmelanotide, allowing its use for the treatment of hypothalamic obesity in adults and pediatric patients aged ≥4 years. Based on data from the phase 3 TRANSCEND trial, which demonstrated setmelanotide’s greater body mass index (BMI) reducing capacity compared to placebo, setmelanotide is a major step forward for a historically rare disease with very few options for treatment.


FDA Approves Updated Starting Dose Guidelines for Inhaled Insulin Powder (Afrezza)


On January 26, 2026, parent company MannKind Corporation announced the FDA’s approval of an updated label for insulin human inhalation powder (Afrezza), providing guidance for starting doses when switching from multiple daily injections or insulin pump mealtime therapy in patients with T1D. The decision was in part due to the phase 4 INHALE-3 trial, which demonstrated improved postprandial glucose outcomes after converting to inhaled insulin with the new dose.


FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2D


On January 12, 2026, Medtronic’s MiniMed go Smart Multiple Daily Injection app was approved for the use of patients aged ≥7 years with T1D or T2D, as well as for children between 2-6 years with adult supervision. The device integrates the InPen smart insulin pen and the Instinct sensor, both of which were developed by Abbott, to provide users with missed dose alerts to minimize glucose highs, action-oriented guidance in the event of a missed or miscalculated dose, and a dose calculator to help simplify decision-making.


VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2D


Pfizer’s investigational ultra-long-acting, fully biased GLP-1 RA displayed substantial weight loss compared to placebo in patients with overweight or obesity but without T2D. VESPER-3, an ongoing 64-week trial, includes 4 separate titration and dosage arms and a placebo comparator. By week 28, arm 1 saw a 10% placebo-adjusted weight loss, while arm 3 exhibited 12.3%. Pfizer has announced that full data from the trial will be presented on June 6 at the American Diabetes Association’s 86th Scientific Sessions.


ACHIEVE-3: Orforglipron Achieves Superiority to Oral Semaglutide in Poorly Controlled T2D


Eli Lilly announced detailed results from ACHIEVE-3 on February 26, 2026. The trial demonstrated orforglipron’s superiority to oral semaglutide for the treatment of T2D inadequately controlled with metformin. Orforglipron led to an A1c reduction of 2.2% in the 36 mg treatment arm and by 1.9% in the 12 mg arm, compared to 1.1% and 1.4% in semaglutide 7 mg and 14 mg. Similarly, patients given orforglipron saw a body weight reduction of 9.2% in the 36 mg arm and 6.7% in the 12 mg arm, compared to 3.7% and 5.3% in the semaglutide 7 mg and 14 mg arms, respectively.


Retatrutide Delivers A1C Reduction, Weight Loss in Phase 3 TRANSCEND-T2D-1 Trial


The TRANSCEND-T2D-1 trial data, published on March 19, 2026, demonstrated Eli Lilly’s groundbreaking GIP/GLP-1/glucagon triple agonist and its efficacy as an adjunct to diet and exercise in patients with T2D and inadequate glycemic control. 3 separate doses of retatrutide were pitted against placebo in adults with T2D – patients given the 12 mg dose lost an average of 28.7% of their body weight at 68 weeks. Full data will be presented at the American Diabetes Association conference in June 2026.


Diabetes Dialogue: Orforglipron, Retatrutide, and Other GLP-1 Updates


In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss an onslaught of news regarding GLP-1 RAs and similar medications. Orforglipron’s exceptional results from ACHIEVE-3, retatrutide’s superiority to placebo in T2D, and early phase 2 data on Novo Nordisk’s investigative triple agonist UBT251 take center stage as Isaacs and Bellini cover the expanding landscape of these practice-changing medications.


Diabetes Dialogue: Oral Ozempic and the Risks of Compounding Formulas


In this episode, Isaacs and Bellini cover a landscape of oral GLP-1s, between Ozempic, Wegovy, and Rybelsus – the latter now known as Ozempic as well. Additionally, the cohosts discuss the controversy surrounding Hims and Hers, a nutrition/lifestyle company marketing lower-cost, compounded oral GLP-1s. The company is currently facing down a lawsuit by Novo Nordisk, given that they potentially infringed upon the latter’s proprietary SNAC technology. Isaacs and Bellini warn that similar formulations to the Hims and Hers line may lack regulatory oversights, potentially resulting in direct risk to patients.

Endocrinology entered 2026 with multiple FDA actions and pivotal readouts spanning diabetes, obesity, and hypothalamic obesity. Regulatory milestones included the first once-weekly basal insulin (insulin icodec) for T2D, label updates enabling clearer Afrezza starting-dose conversions in T1D, expansion of setmelanotide to acquired hypothalamic obesity, and clearance of a smart MDI support app integrating connected pen/sensor technology. Late-stage trials highlighted potent glycemic and weight effects from oral orforglipron versus oral semaglutide and from triple-agonist retatrutide, alongside encouraging obesity data for Pfizer’s ultra-long GLP-1 RA.

Catch up on FDA decisions, new GLP-1 agonists, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Q1 2026 Recap: Endocrinology News and Updates

Mark G. Lebwohl, MD, the dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai,

Defining Treatment Goals and Addressing Unmet Needs in Psoriasis

In this episode, ‘Defining Treatment Goals and Addressing Unmet Needs in Psoriasis,’ the expert dermatologists explore the evolution of patient expectations and the clinical necessity of aggressive disease management. Dr. Mark Lebwohl explains that his primary objective aligns with the National Psoriasis Foundation treat to target guidelines, which aim for less than 1% body surface area involvement. He argues that this goal is vital because psoriasis is a systemic inflammatory condition rather than a localized skin issue. Dr. Lebwohl notes that severe psoriasis can triple the risk of heart attacks in young patients, making effective treatment essential for cardiovascular and joint health.

Dr. Tina Bhutani-Jacques adds that while patients may be hesitant to commit to lifelong therapy, the risks of under treatment often outweigh the potential side effects of modern medications. She points out that achieving total clearance is now a realistic possibility for many patients, though significant unmet needs remain. The experts identify specific challenges such as nail psoriasis and palmoplantar psoriasis, where current therapies still struggle to produce consistent results. They also discuss the need for better management of psoriatic arthritis and the pursuit of PASI 100 scores across more of the patient population. Reflecting on the history of the field, the doctors contrast the dangerous and less effective treatments of the past with the current landscape, concluding that striving for tighter disease control is a necessary standard of care to prevent long term comorbidities.

The next episode in this series, ‘The Role of TYK2 Inhibitors in Modern Psoriasis Care,’ features the panelists discussing the mechanism of action of TYK2 inhibitors and how they provide a highly selective oral alternative to injectable biologics. Dr. Bhutani-Jacques and Dr. Lebwohl explain how these agents block specific cytokine signaling while maintaining a favorable safety profile compared to traditional JAK inhibitors.

Expert dermatologists urge aggressive psoriasis control to prevent heart and joint risks, highlight unmet needs, and preview TYK2 inhibitors as a safer oral option.

Addressing Challenges in Psoriasis with Evolving Treatment Landscape

Welcome back to another HCPLive Peers & Perspectives series. In this episode titled, ‘Addressing Challenges in Psoriasis with Evolving Treatment Landscape,’ Dr. Tina Bhutani-Jacques joins Dr. Mark Lebwohl to discuss the current state of psoriasis care. The conversation centers on the emergence of TYK2 inhibitors as a distinct class of treatment and how these agents provide new opportunities for patient management.

Dr. Lebwohl reflects on the dramatic evolution of psoriasis therapy, noting that while practitioners now have approximately 15 highly effective options, the abundance of choices presents its own challenges. He emphasizes that selecting the right treatment is a scientific process rather than an art form. The decision depends heavily on individual patient factors including the extent of the disease and a wide array of comorbidities. Dr. Lebwohl highlights that common conditions such as obesity, joint pain, cardiovascular risk, diabetes, and inflammatory bowel disease significantly influence which medication is most appropriate for a specific person. He also notes the importance of screening for infections like HIV or tuberculosis before finalizing a treatment plan. The experts conclude that the complexity of the psoriasis patient population requires a nuanced approach to positioning newer oral agents like TYK2 inhibitors. This episode sets the stage for a deeper dive into the latest efficacy and safety data that help clinicians navigate these real world treatment hurdles.

In the next episode, ‘Defining Treatment Goals and Addressing Unmet Needs in Psoriasis’, panelists will continue their discussion on psoriasis and highlight the importance of the treat to target approach while identifying remaining gaps in care for difficult to treat areas like the palms and soles. The experts emphasize that achieving clear skin is not just about aesthetics but about reducing systemic inflammation and long term cardiovascular risks.

Explore how TYK2 inhibitors reshape psoriasis care, as experts weigh comorbidities, infection screening, and treat-to-target goals to overcome real-world treatment hurdles.

Ali Rezaie, MD, is medical director of the GI Motility Program at Cedars-Sinai.

New long-term data link antidepressant use in IBS to higher mortality risk. Rezaie explains key findings and clinical implications.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Are We Overlooking Long-Term Risks in IBS Management? New 20-Year Safety Data, With Ali Rezaie, MD

Catch up on major trial results, groundbreaking guideline updates, and more.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Atherosclerotic Cardiovascular Disease

Arrhythmia

Dyslipidemia

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Structural Heart Disease

Cardiomyopathy

Venous Thromboembolism

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Q1 2026 Recap: Cardiology News and Updates

Simon Davies, MD, is  a consultant nephrologist at the University Hospital of North Midlands and Professor of Nephrology and Dialysis Medicine, as well as director of the Institute for Applied Clinical Sciences at Keele University.

Davies breaks down the gaps to at-home dialysis access and the future of global collaboration. 

Gaps in Home Dialysis Access Persist Globally, With Simon Davies, MD

Phase 3 ONWARD data for the investigational TYK2 inhibitor envudeucitinib join a rapidly crowding oral psoriasis space.


Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

How Envudeucitinib May Fit Into the Evolving Oral Psoriasis Landscape, With Andrew Blauvelt, MD, MBA

In the final episode, ‘Risk-Based Management in Hypercortisolism,’ the panelists explored how to approach hypercortisolism management in the absence of widely accessible, targeted therapies, emphasizing a risk-based treatment paradigm. 

Video Series

Risk-Based Management in Hypercortisolism

In ‘Emerging Therapies in Hypercortisolism,’ our panel explores the evolving therapeutic landscape for hypercortisolism and the future direction of treatment development.

Emerging Therapies in Hypercortisolism

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

March 2026 endocrinology updates include key FDA approvals, advances in diabetes and obesity therapies, and innovations in insulin delivery and rare disease care.

7 Endocrinology Headlines You Missed in March 2026

In this episode, ‘Hypercortisolism and Cardiovascular Risk Management,’ the panelists explore the broader implications of hypercortisolism on cardiovascular risk and the role of cardiologists in comprehensive patient management.

Hypercortisolism and Cardiovascular Risk Management

This episode, titled ‘Hypercortisolism Treatment and Care Pathways,’ features panelists discussing the management of hypercortisolism following diagnosis, with a focus on the roles of cardiologists and endocrinologists in coordinating care. 

Hypercortisolism Treatment and Care Pathways

In ‘Hypertension Management in Hypercortisolism,’our panel explores the clinical implications of emerging data on hypercortisolism and outline a forward-looking approach to hypertension management.

Latest News

The Mechanics Behind PAH Diagnosis and Management, With Anjali Vaidya, MD

Q1 2026 Recap: Nephrology News and Updates

Q1 2026 Recap: Endocrinology News and Updates

Defining Treatment Goals and Addressing Unmet Needs in Psoriasis

Addressing Challenges in Psoriasis with Evolving Treatment Landscape